We are asking all faculty members to strictly respect the given time limits.
**MAIN ARENA 1**

15:00 – 16:30  
**Current concepts and advances for long femoropopliteal lesions and in-stent restenosis**

**CHAIRMAN:**  
Tony Das

**MODERATOR:**  
Jörn Balzer  
Francesco Liistro  
Peter Gaines  
Marc Bosiers  
Sabine Steiner  
Michael Werk  
Roberto Gandini

15:52 – 16:15  
Live case transmission from Leipzig

16:15 – 16:20  
Excimer laser atherectomy for in-stent restenosis: Results of the EXCITE trial

**Eric Dippel**

16:20 – 16:25  
The Copa Cabana study: DEB vs. POBA in in-stent restenosis

**Gunnar Tepe**

16:25 – 16:30  
The cost economic value of DCB

**Konstantinos Katsanos**

15:47 – 15:52  
The Leipzig experience with DCB, conventional, and interwoven nitinol stents for complex SFA disease

**Sabine Steiner**

15:42 – 15:47  
The endoluminal bypass – the best solution for long lesions and ISR?

**Peter Soukas**

15:07 – 15:12  
After 10,000+ DCB: How has this technology changed our clinical practice for complex SFA lesions?

**Andrej Schmidt**

15:12 – 15:19  
One-year follow-up of the DEBAS STUDY

**Patrice Mwipatayi**

15:19 – 15:26  
Is the combination of DCB and bare metal stents as effective as DES? The BIOLUX 4EVER trial

**Marc Bosiers**

---

*We are asking all faculty members to strictly respect the given time limits.*
# Programme

**LEIPZIG INTERVENTIONAL COURSE**

---

**Konstantinos Katsanos**  
*Page 3/4*

**Tuesday, January 27, 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:26 – 15:42</td>
<td>Live case transmission from Dendermonde</td>
</tr>
</tbody>
</table>
| 15:00 – 15:07 | What works best for long SFA disease? A review of the evidence  
*Marc Bosiers* |

---

*We are asking all faculty members to strictly respect the given time limits.*
**Wednesday, January 28, 2015**

**MAIN ARENA 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 12:30</td>
<td>Symposium: Unique technologies for the treatment of peripheral artery disease</td>
</tr>
<tr>
<td></td>
<td>CHAIRMAN: Michel Reijnen</td>
</tr>
<tr>
<td></td>
<td>MODERATOR: Eric Verhoeven</td>
</tr>
<tr>
<td>11:00 – 11:05</td>
<td>Introduction by the chairman</td>
</tr>
<tr>
<td>11:05 – 11:15</td>
<td>Collateral damage in endovascular treatment of SFA occlusive disease: fact or fiction?</td>
</tr>
<tr>
<td>11:15 – 11:35</td>
<td>Endovascular treatment with the new generation stent design of the GORE® TIGRIS® Vascular Stent</td>
</tr>
<tr>
<td>11:15 – 11:35</td>
<td>Live case transmission from Dendermonde</td>
</tr>
<tr>
<td>11:45 – 12:05</td>
<td>Revising dysfunctional and thrombosed dialysis access: my experiences and clinical outcome</td>
</tr>
<tr>
<td>12:05 – 12:15</td>
<td>Discussion and conclusion by the chairman</td>
</tr>
<tr>
<td>12:15 – 12:30</td>
<td>Live case transmission from Leipzig</td>
</tr>
</tbody>
</table>

*We are asking all faculty members to strictly respect the given time limits.*